Generic medicines have a key role to play in the efficient allocation of financial resources for pharmaceutical medicines. In Australia, the current utilisation of generic medicines is comparatively low compared with other Organization for Economic Co-operation and Development countries. This paper discusses the current issues and problems relating to the use of generic medicines in Australia and the role they play in the Pharmaceutical Benefits Scheme, which is a comprehensive system for subsidy of prescription drugs covering the whole population.
Get full access to this article
View all access options for this article.
References
1.
KanavosP. (1999) ‘Financing pharmaceuticals in transition economies’, Croatian Medical Journal, Vol. 40, No. 2, pp. 244–259.
2.
EssS. M.SchneeweissS.SzucsT. D. (2003) ‘European healthcare policies for controlling drug expenditure’, Pharmacoeconomics, Vol. 21, No. 2, pp. 89–103.
3.
KirkingD. M.AscioneF. J.GaitherC. A.WelageL. S. (2001) ‘Economics and structure of the generic pharmaceutical industry’, Journal of the American Pharmaceutical Association, Vol. 41, No. 4, pp. 578–584.
4.
EversP. (2001) ‘Generics: Past, present and future’, Pharmaceutical Times, October, pp. 30–32.
5.
Commonwealth Department of Health and Ageing (2003) ‘Securing the future of the Pharmaceutical Benefits Scheme’, available at http://www.health.gov.au.budget2002/fact/hfact1.htm, accessed 30th July, 2003.
6.
DonovanJ. (2003) ‘Is there a role for generic medicines in the Pharmaceutical Benefits Scheme?’Health Issues, No. 75, Winter, pp. 9–11.
LofgrenH. (2004) ‘Generic drugs: International trends and policy developments in Australia’, Australian Health Review, Vol. 27, No. 1, pp. 39–48.
9.
McGavockH. (2001) ‘Generic substitution: Issues relating to the Australian experience’, Pharmacoepidemiology and Drug Safety, Vol. 10, No. 6, pp. 555–556.
10.
McGavockH. (1997) ‘Strategies to improve the cost effectiveness of general practitioner prescribing: An international perspective’, Pharmacoeconomics, Vol. 12, No. 3, pp. 307–311.
11.
BirkettD. J. (2003) ‘Generics equal or not’, Australian Prescriber, Vol. 26, pp. 85–87.
12.
Therapeutics Goods Administration (1994) ‘Australian Guidelines for Registration of Drugs’, Vol. 1, Prescription and Other Specified Drug Products, 2nd edn., Australian Government Printing Service, Canberra.
13.
BirkettD. J.MitchellA. S.McManusP. (2003) ‘A cost-effectiveness approach to drug subsidy and pricing in Australia’, Health Affairs, Vol. 20, No. 3, pp. 104–114.
14.
Commonwealth Department of Health and Ageing (2004) ‘Schedule of pharmaceutical benefits for approved pharmacists and medical practitioners effective from 1 February 2004’, National Capital Printing, Canberra, Australia.
15.
McManusP.BirkettD. J.DudleyJ.StevensA. (2001) ‘Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia’, Pharmacoepidemiology and Drug Safety, Vol. 10, No. 4, pp. 295–300.
16.
McManusP.DonnelyN.HenryD. (1996) ‘Prescription drug utilization following patient co-payment changes in Australia’, Pharmacoepidemiology and Drug Safety, Vol. 5, pp. 385–392.
17.
Pharmaceutical Benefits Pricing Authority (2003) ‘Annual report for the year ended 30 June 2003’, Australian Government Printing Service, Canberra.
18.
BrandP.ClearP.KeenS. (1995) ‘Brand substitution’, Australian Pharmacist, Vol. 14, pp. 646–649.
19.
NationR.SansomL. (1994) ‘Bioequivalence requirements for generic products’, Pharmacology and Therapeutics, Vol. 62, pp. 41–55.
20.
HarveyK. J. (2002) ‘Securing the future of the Pharmaceutical Benefits Scheme? The drawing board: An Australian review of public affairs’, available at http;//ww.econ.usyd.edu.au/drawingboard, accessed 30th July, 2003.
21.
HenryD. (1997) ‘Prescribing costs: Whose responsibility?’, Australian Prescriber, Vol. 20, No. 2, pp. 26–27.
22.
Productivity Commission (2001) International Pharmaceutical Price Differences. Research Report, AusInfo, Canberra, Australia.
23.
Department of Veterans Affairs (2004) ‘Pharmacy Benefits Management Strategic Healthcare Group: Drug and pharmaceutical prices in federal supply schedule’, available at http://www.vapbm.org/PBM/prices.htm, accessed 11th March, 2004.
24.
FichamJ.WertheimerA. (eds) (1998) Pharmacy and the US Health Care System, 2nd edn, Pharmaceutical Products Press, New York, NY.
25.
KingD. R.KanavosP. (2002) ‘Encouraging the use of generic medicines: Implications for transition economies’, Croatian Medical Journal, Vol. 43, No. 4, pp. 462–469.
26.
BrittH.MillerG.CharlesJ. (2001) General Practice Activity in Australia 2000–01, University of Sydney and Australian Institute of Health and Welfare, Canberra, Australia.
27.
MessengerA. (1995) ‘Substitution bitter pill to swallow for some’, Australian Doctor, 4th June, p. 16.
28.
ScuderiM. (2002) ‘Generic substitution in a Brisbane community pharmacy’, Australian Pharmacist, Vol. 21, pp. 116–121.
29.
KirkingD. M.GaitherC. A.AscioneF. J.WelageL. S. (2001) ‘Physicians' individidual and organizational views on generic medications’, Journal of the American Pharmaceutical Association, Vol. 41, No. 5, pp. 718–722.
30.
BanahanB. F.IIIKolassaE. M. (1997) ‘A physician survey on generic drugs and substitution of critical dose medications’, Archives of Internal Medicine, Vol. 157, No. 18, pp. 2080–2088.
31.
McGettiganP.McManusJ.O'SheaB. (1997) ‘Low rate of generic prescribing in the Republic of Ireland compared to England and Northern Ireland: Prescribers' concerns’, Irish Medical Journal, Vol. 90, No. 4 pp. 146–147.
32.
TilyardM. W.DoveyS. M. (1990) ‘General practitioners' views on generic medication and substitution’, New Zealand Medical Journal, Vol. 103, pp. 318–320.
33.
KirkingD. M.AscioneF. J. (2001) ‘Perspectives on generic pharmaceuticals: Some conclusions’, Journal of the American Pharmaceutical Association, Vol. 41, No. 6, pp. 826–828.
34.
GaitherC. A.KirkingD. M.AscioneF. J.WelageL. S. (2001) ‘Consumers' views on generic medications’, Journal of the American Pharmaceutical Association, Vol. 41, No. 5, pp. 729–736.
35.
BrookerC. (2003) ‘No simple message on generic substitution’, Pharmacy News, August, p. 8.
36.
PodulkaM.KrautkramerK.AmersonD. (1989) ‘Consumers' attitudes toward generic drugs’, Journal of Pharmaceutical Marketing Management, Vol. 4, No. 1, pp. 93–104.
37.
KendallK. W.NgS.SchonerB. (1991) ‘Consumer response to generic/chemically equivalent drugs’, Journal of Public Policy and Marketing, Vol. 10, No. 2, pp. 182–201.
38.
FoggS. (2003) ‘Informing the consumer’, Australian Prescriber, Vol. 26, No. 1, pp. 2–3.
39.
DowellJ. S.SnaddenD.DunbarJ. A. (1996) ‘Rapid prescribing change, how do patients respond?’, Social Science & Medicine, Vol. 43, No. 11, pp. 1543–1549.
40.
SmeatonJ. (2000) ‘The generics market’, Australian Journal of Pharmacy, Vol. 81, pp. 540–542.
41.
Food and Drug Administration (2002) ‘What are generic drugs?’Center for Drug Evaluation and Research, available at http://www.fda.gov/cder/ogd/inex.htm, accessed 30th December, 2002.
42.
Food and Drug Administration (2002) ‘Generic drugs: What you need to know’, FDA Consumer, Vol. 36, No. 5, p. 24.
43.
WhynesD.BainesD.TolleyK. G. P. (1997) ‘Fundholding and the costs of prescribing: Further results’, Journal of Public Health Medicine, Vol. 19, No. 1, pp. 18–22.
44.
WilsonR. P. H.BuchanI.WalleyT. (1995) ‘Alterations in prescribing by general practitioner fundholders: An observational study’, British Medical Journal, Vol. 311, No. 7016, pp. 1347–1350.
45.
BatemanD. N.CampbellM.DonaldsonL. J. (1996) ‘A prescribing incentive scheme for non-fundholding general practices: An observational study’, British Medical Journal, Vol. 313, No. 7056, pp. 535–538.
46.
BeilbyJ. J.PekarskyB. (2002) ‘Fundholding: Learning from the past and looking to the future’, Medical Journal of Australia, Vol. 176, pp. 321–325.
47.
PritchardD. A.BeilbyJ. J. (1996) ‘Issues for fundholding in Australian general practice’, Medical Journal of Australia, Vol. 164, pp. 215–218.
48.
HuttinC. (1996) ‘A critical review of the remuneration systems for pharmacists’, Health Policy, Vol. 36, No. 1, pp. 53–68.
49.
GarattiniL.TediosiF. (2000) ‘A comparative analysis of generics markets in five European countries’, Health Policy, Vol. 51, pp. 149–162.
50.
GarattiniL.SalvioniF. (1996) ‘Distribution margins: A European overview’, Pharma Pricing Review, Vol. 1, pp. 154–158.
51.
BachynskyJ. A. (1992) ‘Canada’, in SpiveyR. N.WertheimerA.RuckerD. T. (eds) International Pharmaceutical Services: The Drug Industry and Pharmacy Practice in Twenty-Three Major Countries of the World, Haworth Press, New York, NY, p. 75.
52.
SzeinbachS. L. (1998) ‘Drug distribution’, in FichamJ.WertheimerA. (eds) Pharmacy and the U.S. Health Care System, 2nd edn, Haworth Press, New York, NY, pp. 317–334.
53.
TeagardenJ. R. (2003) ‘The allure of generic drugs’, Hospital Pharmacy, Vol. 38, No. 11, pp. 1079–1081, 1085.
54.
Department of Health and Ageing (2000) ‘Third Community Pharmacy Agreement between The Commonwealth of Australia and The Pharmacy Guild of Australia — 1 July 2000 to 30 June 2005’, available at http://www.health.gov.au/pbs/healthpro/pharmacy/pharmacyagree.pdf, accessed 15th May, 2004.
ArmstrongD.ReyburnH.JonesR. (1996) ‘A study of general practitioners' reasons for changing their prescribing behaviour’, British Medical Journal, Vol. 312, No. 7036, pp. 949–952.
57.
SeneviratneS. L.GunatilakeS. B.AdhikariA. A. (1998) ‘Changing prescribing behaviour: Early low dose aspirin in suspected acute myocardial infarction’, International Journal of Cardiology, Vol. 67, No. 3, pp. 237–240.
58.
SouthM.RoyleJ.StarrM. (2003) ‘A simple intervention to improve hospital antibiotic prescribing’, Medical Journal of Australia, Vol. 178, No. 5, pp. 207–209.
59.
SoumeraiS.McLaughlinT.AvornJ. (1989) ‘Improving drug prescribing in primary care: A critical analysis of the experimental literature’, The Milbank Quarterly, Vol. 67, No. 2, pp. 269–305.
60.
GehlbachS. H.WilkinsonW. E.HammondN. E. (1984) ‘Improving drug prescribing in a primary care practice’, Medical Care, Vol. 22, No. 3, pp. 193–201.
61.
SnellB. F. (1992) ‘Rational prescribing: The challenge for medical educators’, Medical Journal of Australia, Vol. 156, pp. 352–354.
62.
CampbellM.SmithM.BeaneyA. (1995) ‘The pros and cons of generic medicines’, Pharmacoeconomics, Vol. 8, No. 4, pp. 362–364.
